These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 32039631)
1. Prognostic alternative splicing regulatory network of splicing events in acute myeloid leukemia patients based on SpliceSeq data from 136 cases. Xie ZC; Gao L; Chen G; Ma J; Yang LH; He RQ; Li MW; Cai KT; Li TT; Peng ZG Neoplasma; 2020 May; 67(3):623-635. PubMed ID: 32039631 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases. He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970 [TBL] [Abstract][Full Text] [Related]
3. Identification of survival-related alternative splicing signatures in acute myeloid leukemia. Zhang B; Yang L; Wang X; Fu D Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34212178 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive Characterization of the Prognosis Value of Alternative Splicing Events in Acute Myeloid Leukemia. Chen XX; Zhu JH; Li ZP; Xiao HT; Zhou H DNA Cell Biol; 2020 Jul; 39(7):1243-1255. PubMed ID: 32543226 [TBL] [Abstract][Full Text] [Related]
5. Effects of Alternative Splicing Events on Acute Myeloid Leukemia. Chen SL; Dai YJ; Hu F; Wang Y; Li H; Liang Y DNA Cell Biol; 2020 Nov; 39(11):2040-2051. PubMed ID: 32915082 [TBL] [Abstract][Full Text] [Related]
6. Role of alternative splicing signatures in the prognosis of glioblastoma. Xie ZC; Wu HY; Dang YW; Chen G Cancer Med; 2019 Dec; 8(18):7623-7636. PubMed ID: 31674730 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases. Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199 [TBL] [Abstract][Full Text] [Related]
8. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma. Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value and potential function of splicing events in prostate adenocarcinoma. Huang ZG; He RQ; Mo ZN Int J Oncol; 2018 Dec; 53(6):2473-2487. PubMed ID: 30221674 [TBL] [Abstract][Full Text] [Related]
10. Characterization of alternative splicing events and prognostic signatures in breast cancer. Han P; Zhu J; Feng G; Wang Z; Ding Y BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836 [TBL] [Abstract][Full Text] [Related]
11. Identification of a prognostic alternative splicing signature in oral squamous cell carcinoma. Zhang S; Wu X; Diao P; Wang C; Wang D; Li S; Wang Y; Cheng J J Cell Physiol; 2020 May; 235(5):4804-4813. PubMed ID: 31637730 [TBL] [Abstract][Full Text] [Related]
12. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data. Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163 [TBL] [Abstract][Full Text] [Related]
13. Alternative Splicing Events as Indicators for the Prognosis of Uveal Melanoma. Wan Q; Sang X; Jin L; Wang Z Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32098099 [TBL] [Abstract][Full Text] [Related]
14. Prognostic index of aberrant mRNA splicing profiling acts as a predictive indicator for hepatocellular carcinoma based on TCGA SpliceSeq data. Wu HY; Peng ZG; He RQ; Luo B; Ma J; Hu XH; Dang YW; Chen G; Pan SL Int J Oncol; 2019 Aug; 55(2):425-438. PubMed ID: 31268164 [TBL] [Abstract][Full Text] [Related]
15. Exploration of predictive and prognostic alternative splicing signatures in lung adenocarcinoma using machine learning methods. Cai Q; He B; Zhang P; Zhao Z; Peng X; Zhang Y; Xie H; Wang X J Transl Med; 2020 Dec; 18(1):463. PubMed ID: 33287830 [TBL] [Abstract][Full Text] [Related]
16. Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas. Yang X; Huang WT; He RQ; Ma J; Lin P; Xie ZC; Ma FC; Chen G J Transl Med; 2019 Aug; 17(1):283. PubMed ID: 31443718 [TBL] [Abstract][Full Text] [Related]
17. Identification of novel prognostic alternative splicing signature in papillary renal cell carcinoma. Duan Y; Zhang D J Cell Biochem; 2020 Jan; 121(1):672-689. PubMed ID: 31407370 [TBL] [Abstract][Full Text] [Related]
18. Prognostic alternative mRNA splicing signatures and associated splicing factors in acute myeloid leukemia. Jin P; Tan Y; Zhang W; Li J; Wang K Neoplasia; 2020 Sep; 22(9):447-457. PubMed ID: 32653835 [TBL] [Abstract][Full Text] [Related]
19. Systematic analysis and prediction model construction of alternative splicing events in hepatocellular carcinoma: a study on the basis of large-scale spliceseq data from The Cancer Genome Atlas. Yang L; He Y; Zhang Z; Wang W PeerJ; 2019; 7():e8245. PubMed ID: 31844595 [TBL] [Abstract][Full Text] [Related]
20. Systematic Profile Analysis of Prognostic Alternative Messenger RNA Splicing Signatures and Splicing Factors in Head and Neck Squamous Cell Carcinoma. Xing L; Zhang X; Tong D DNA Cell Biol; 2019 Jul; 38(7):627-638. PubMed ID: 31025877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]